Skip to main content
. 2018 Feb 8;9(18):14539–14551. doi: 10.18632/oncotarget.24465

Figure 4. MiR-125b/BAK1 signaling impairs the doxorubicin response of NPM-ALK-positive ALCL cells.

Figure 4

In NPM-ALK(+) ALCL KARPAS-299 and COST cells transfected with a mimic miR-125b (miR-125b) or negative control microRNA (miR-CTL). (A) Western blotting analysis of BAK1 and GAPDH protein levels in cells transfected with a mimic miR-125b (miR-125b) or negative control microRNA (miR-CTL). Measurement of caspase 3/7 activity (B) and western blotting analyses of BAK1 and GAPDH protein levels (C) in cells treated with doxorubicin and transfected with either miR-CTL or miR-125b mimics. Densitometric analysis was performed using GeneTools software from Syngene. *P < 0.05 and **P < 0.001; unpaired 2-tailed Student's t test.